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Abstract
Background: Duchenne muscular dystrophy (DMD), caused by mutations in the dystrophin gene,
is lethal. In contrast, dystrophin-deficient mdx mice recover due to effective regeneration of
affected muscle tissue. To characterize the molecular processes associated with regeneration, we
compared gene expression levels in hindlimb muscle tissue of mdx and control mice at 9 timepoints,
ranging from 1–20 weeks of age.
Results: Out of 7776 genes, 1735 were differentially expressed between mdx and control muscle
at at least one timepoint (p < 0.05 after Bonferroni correction). We found that genes coding for
components of the dystrophin-associated glycoprotein complex are generally downregulated in the
mdx mouse. Based on functional characteristics such as membrane localization, signal transduction,
and transcriptional activation, 166 differentially expressed genes with possible functions in
regeneration were analyzed in more detail. The majority of these genes peak at the age of 8 weeks,
where the regeneration activity is maximal. The following pathways are activated, as shown by
upregulation of multiple members per signalling pathway: the Notch-Delta pathway that plays a role
in the activation of satellite cells, and the Bmp15 and Neuregulin 3 signalling pathways that may
regulate proliferation and differentiation of satellite cells. In DMD patients, only few of the identified
regeneration-associated genes were found activated, indicating less efficient regeneration
processes in humans.
Conclusion:  Based on the observed expression profiles, we describe a model for muscle
regeneration in mdx mice, which may provide new leads for development of DMD therapies based
on the improvement of muscle regeneration efficacy.
Background
Duchenne muscular dystrophy (DMD) is caused by muta-
tions in the gene encoding dystrophin, a subsarcolemmal
protein functioning within the dystrophin-associated
glycoprotein complex (DGC)[1,2]. This complex connects
the intracellular cytoskeleton to the extracellular matrix.
The DGC is concentrated at the Z-lines of the sarcomere
and confers the transmission of force across the muscle
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fibre[3]. Disruption of this link results in membrane
instability, which eventually leads to sarcolemmal rup-
tures[4,5]. Influx of extracellular calcium alters molecular
processes like muscle contraction and activates proteolytic
activity. Affected muscle fibres become necrotic or apop-
totic, and release mitogenic chemoattractants, which initi-
ate inflammatory processes [6-8]. Cycles of degeneration
and regeneration eventually lead to irreversible muscle
wasting and replacement by fibrotic and adipose tissue.
Muscle has the potential to regenerate by activation of
undifferentiated myogenic precursor cells (satellite cells),
which are normally quiescent and situated between the
basal membrane and the myofibers[9,10]. Upon activa-
tion, satellite cells proliferate and divide asymmetrically,
with the daughter cells having divergent cell fates[11].
Only one of the daughter cells differentiates, progresses
towards the myoblast-stadium, and subsequently fuses
with other myoblasts or with damaged muscle fibres to
induce muscle fibre repair. The other daughter cell
remains in a proliferating state or returns to quies-
cence[12]. Genetic mutations responsible for DMD are
also present in satellite cells. Hence, the ability to restore
normal muscle function remains obstructed. A small
number of muscle fibres are able to produce functional
dystrophin, mostly due to secondary mutations in myo-
genic precursor cells which restore the reading frame[13].
However, these so-called revertant fibres are in a too small
minority to alleviate the pathology of the dystrophin-defi-
ciency. Exhaustion of the satellite cell pool due to degen-
eration and regeneration cycles is thought to critically
contribute to the disease[14].
The mdx mouse model for DMD has a spontaneous muta-
tion in exon 23 of the Dmd gene, introducing a premature
stopcodon[15,16]. The pathology of the mdx  mouse is
characterized by histologically well-defined stages with
similarity to the human pathology. Neonatal muscle tis-
sue appears to be unaffected. Necrotic or apoptotic proc-
esses in combination with inflammation emerge at
approximately 3 weeks of age[15]. Regeneration processes
are initiated around the age of 6 weeks and continue while
alternating with ongoing degeneration until 12 weeks of
age [17-19]. Contrary to the lethal human pathology, the
mdx mouse somehow recovers from the progressive mus-
cle wasting, and does not show the accumulation of con-
nective and adipose tissue[17,20]. However, mdx mice do
show a decline in their regeneration capacity at advanced
age (>65 weeks), while necrotic processes persist[21].
Since the degeneration processes are similar to those seen
in human pathology, the regenerational differences may
hold one of the clues of restoration of proper muscle
function.
Although previous studies have studied gene expression
levels in the mdx mouse [22-27], regeneration processes
were not studied in full detail. We studied the regenera-
tion process through genome-wide monitoring of gene
expression levels[28] in healthy control and mdx mice at 9
time points from 1 to 20 weeks of age, while putting
emphasis on time points where regenerative activity is
maximal (6–12 weeks), a period which was not analysed
in detail in a previous time course study[23]. According to
the temporal gene expression profiles, we determined
which pathways are active during regeneration with
respect to normal muscle aging. The majority of identified
genes presented in this study have not been described
before and provide a substantial addition to the elucida-
tion of the temporal phasing of degeneration and regener-
ation. By careful annotation based on existing literature,
new light is shed on the pathology and subsequent recov-
ery in the mdx mouse. Furthermore, we compared gene
expression profiles to those of human DMD patients and
found only modest overlap in regeneration-associated
genes. This confirms that regeneration is no longer an
active process at the age at which the patients were pro-
filed (5–12 years old).
Results and discussion
Global comparison of mdx and control mice
Gene expression levels were determined in hindlimb mus-
cle tissue from mdx and control mice at 9 time points,
ranging from 1 to 20 weeks. Differential gene expression
levels were calculated per time point by subtraction of the
average normalized intensities of control samples from
those of the mdx samples to correct for normal aging proc-
esses. The effects of the normal aging processes on gene
expression are relatively minor, and are discussed below.
Statistical significance was calculated per time point by
performing a Student's t-test. Differential gene expression
was considered significant when p-values were lower than
0.05 after applying a Bonferroni correction for multiple
testing (p ≤ 6.43 × 10-6). Out of 7,776 temporal gene
expression profiles 1,735 were selected, which satisfied
the significance criterion at one or more time points [see
Additional file 1].
The number of differentially expressed genes per time
point changes considerably during the time course, an
effect also shown in a previous study by Porter et al.[27]
(Figure 1). The number of differentially expressed genes
peaks at the age of 8–12 weeks, coinciding with the period
of maximal muscle regeneration. Interestingly, also at the
first two time points (1 and 2.5 weeks of age), where the
histology of the mdx muscle is not different from that of
control mice, a large number of genes was differentially
expressed, indicating differences in muscle development
in dystrophin-deficient animals. The majority of these
genes (553/677 and 355/407, respectively) also showBMC Genomics 2005, 6:98 http://www.biomedcentral.com/1471-2164/6/98
Page 3 of 15
(page number not for citation purposes)
statistically significant differences in expression at later
time points. This overlap can be explained by the assump-
tion that the repertoire of gene products used for muscle
growth and development also functions in muscle
regeneration.
In this report we will describe the expression changes of
two main categories in more detail: genes coding for pro-
teins within the costamer and the dystrophin-associated
glycoprotein complex (DGC), and genes involved in
regeneration.
The Dystrophin-Glycoprotein Complex
The effect of dystrophin-deficiency on expression levels of
dystrophin-glycoprotein complex (DGC)-related genes,
or genes with associated functional relevance within the
costamer has not been reported in previous gene expres-
sion profiling studies [22-26], with the exception of the
study of Porter and co-workers[27]. In the Porter study, a
downregulation of dystrophin was reported, but no
changes in gene expression of other components of the
DGC. A selection of 52 genes was made based on an over-
view by Ervasti et al. of members of the costameric protein
network[29] (Additional file 4). According to the statisti-
cal selection criteria, 4 genes were upregulated (Figure 2A)
and 12 were downregulated (Figure 2B) in the mdx
mouse. Although a decrease in dystrophin expression was
found in our study, the stringent statistical criteria were
not met.
Upregulated DGC related genes
We find that the retina-specific isoform of dystrophin
(Dp260) is expressed in skeletal muscle of mdx  mice,
whereas Dp260 cannot be detected in hindlimb muscle of
control mice. Expression of Dp260 was detected by an oli-
gonucleotide probe within the unique first exon of this
transcript. The promoter of the Dp260 isoform resides in
intron 29, downstream of the mdx mutation (exon23).
Transgenic mdx mice, which overexpress Dp260 via an
alpha-actin promoter, show a restoration of a stable asso-
ciation between costameric actin and the sarcolemma, a
re-assembly of the DGC, and an overall alleviation of the
Amount of differentially expressed genes Figure 1
Amount of differentially expressed genes. The number of statistically significantly differentially expressed genes between 
mdx and control mice measured across 9 consecutive timepoints from 1 to 20 weeks in this study (continuous line) are com-
pared to the number of differentially expressed genes found in the study of Porter et al.[27] (dashed line).
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Costameric and DGC related gene expression Figure 2
Costameric and DGC related gene expression. Fold change in gene expression levels between mdx and control muscle 
tissue measured across 9 consecutive timepoints from 1 to 20 weeks of costameric and DGC related genes. Figure 2A shows 
the fold changes of the statistically significantly upregulated genes over time; Figure 2B shows the downregulated genes.
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pathology[30]. Increased transcription initiation of
Dp260 might therefore be a natural adaptation for the
lack of the muscle specific isoform of dystrophin. How-
ever, in contrast to the artificially raised expression by the
alpha-actin promoter, the expression of Dp260 in the mdx
mouse through the original promoter does not seem to be
strong enough to compensate for loss of the full-length
muscle specific isoform.
We found a continuous upregulation of alpha-dystrobre-
vin (Dtna) gene expression with maximum differential
expression at 4 weeks in mdx mice. Dystrobrevin is a phos-
photyrosine-containing protein localized at both the sar-
colemma and the postsynaptic side of the neuromuscular
junction (NMJ), where it binds to either dystrophin or
utrophin [31-34]. Dtna has been described to function as
a signalling mediator within the DGC[34]. Transcription
of Dtna is activated when myoblasts differentiate into
multinucleated myotubes[35]. Newey et al. reported that
Dtna-protein levels are significantly reduced in the mdx
mouse at the sarcolemma, whereas the protein level was
unchanged at the NMJ. This would be consistent with a
stabilizing action of Dtna upon binding to dystrophin or
utrophin, since dystrophin is not present at the sarco-
lemma, whereas utrophin is expressed at the NMJ. They
proposed a model, where localized translation of Dtna
transcripts contributes to synapse formation[36]. Upregu-
lation of Dtna in the mdx  mouse might indicate an
attempt to compensate for the increased turnover of the
protein, in order to stabilize the post-synaptic side of
neuromuscular junctions of affected muscle fibres, and
retain neuronal connection.
Our results show a continuous upregulation of LIM
domain protein 3 (Ldb3, Cypher/ZASP). Studies in Ldb3
knock-out mice demonstrated that ablation of Ldb3 erad-
icates the structural integrity of the Z-line in contracting
striated muscle and causes a severe form of congenital
myopathy[37]. Upregulation of Ldb3 indicates the neces-
sity for stabilization of the Z-line in mdx mice, compensat-
ing the undermining effect of dystrophin-deficiency.
Downregulated DGC related genes
It can be seen that gene expression levels of several core-
proteins of the DGC, e.g. the transmembrane proteins
dystroglycan (Dag1), sarcospan (Sspn), and two members
of the sarcoglycan-complex (Sgcd, Sgcg), are lower in mdx
mice, over the whole time course. Lower expression levels
were also detected in other members of the sarcoglycan
complex (Sgca, Sgcb, Sgce) and in dystrophin (Dmd, oli-
gonucleotide at the 3' end), but these were not statistically
significant. The decrease in expression of DGC-related
genes was most prominent during regeneration (8–12
weeks).
Interestingly, DGC related gene expression levels restore
to pre-regeneration levels subsequent to the regeneration
period, but remain lower than normal (control) level.
Similarly, protein levels of core-proteins of the DGC have
been shown to be severely reduced in dystrophin-defi-
cient mdx mice[38]. It is suggested that the secondary dis-
placement of DGC core-proteins is due to a decrease in
protein synthesis and/or assembly, or due to an increase
in protein degradation. Similarly, in sarcoglycan-deficien-
cies the absence of a single subunit causes the loss or
strong reduction of the entire sarcoglycan protein com-
plex [39-43]. Since our study reveals a downregulation of
mRNA levels of the DGC core-proteins, we conclude that
alterations in transcriptional activity also contribute to the
decrease in protein levels. As transcription of members of
the DGC is likely to be co-ordinately regulated[44], down-
regulation of these members as seen in mdx  mice can
occur via inhibition or downregulation of shared tran-
scriptional activators.
Regeneration
In the mdx mouse, regeneration of affected muscle tissue
is most prominent at the age of 6–12 weeks, after which a
stabilized condition is reached. To identify pathways
active in regeneration, we studied five categories of differ-
entially expressed genes covering major functional charac-
teristics of regenerative tissues (trophic factors, proteases,
membrane associated proteins, signal transduction, and
transcription, Additional file 5). This selection of 166
genes was typed for temporal effects during regeneration,
and the pathways to which they belong. Since signal trans-
duction pathways are still poorly annotated in current
genomic databases, these pathways were constructed from
the literature. In our study, a pathway is only considered
activated or repressed, when multiple members show dif-
ferential gene expression.
Temporal effects during regeneration
Differential gene expression profiles, based on the ratio
between mdx and control mice, were scaled to the first
time point. Differential expression profiles can therefore
be compared independent of the ratio level, which ena-
bles the detection of temporal effects. Using k-means clus-
tering (k = 6), differential gene expression profiles were
classified according to their temporal similarity. The
unscaled temporal effects of mdx and control gene expres-
sion profiles are shown per cluster for the up- and down-
regulated genes separately (Figure 3). Genes, which show
an upregulation in gene expression during the regenera-
tive phase, are present in clusters 1 (n = 27), cluster 2 (n =
36), and cluster 4 (n = 21). The temporal effect is deter-
mined by the gene expression profile of the mdx mouse,
since gene expression is continuously low without tempo-
ral changes in the control mouse. Downregulation of gene
expression in the mdx  mouse during regeneration isBMC Genomics 2005, 6:98 http://www.biomedcentral.com/1471-2164/6/98
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primarily seen in cluster 3 (n = 23). During normal aging,
which can be seen in the control mouse, gene expression
increases until the age of 10 weeks, followed by a slow
decrease. During the regenerative phase in the mdx mouse,
however, the expression of these genes is downregulated
markedly.
Notch-Delta pathway
Gene expression levels of a number of genes functioning
in the Notch-Delta pathway are upregulated (Notch1,
Notch2, Hr), whereas others (Dxd26, Dvl, Dvl2) are
downregulated in the mdx mouse at 8 weeks of age (Figure
4A). The gene expression of Dll3 and Numb are switched
on in the mdx mouse, while no gene expression can be
detected in the control mouse (Supplemental Table 1 [see
Additional file 4]). The differential expression of the
upregulated genes is mostly increased during the regener-
ation period (6 to 12 weeks) (Figure 4A). For several genes
in the Notch-Delta pathway, quantitative RT-PCR experi-
ments were performed to confirm the temporal expres-
sion profiles found on the microarray. In accordance with
Temporal effects during regeneration Figure 3
Temporal effects during regeneration. K-means clustering (k = 6) classifies gene expression profiles according to similar-
ity in temporal patterns based on the scaled differential gene expression levels (grey line). For each cluster the up- and down-
regulated genes are shown separately. Unscaled differential gene expression levels are shown (black line), which are 
representative for the ratio between the mdx gene expression levels (dashed line) and control gene expression levels (small 
dashed line). Relative gene expression levels are obtained after normalization and coincide with the natural logarithm.
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the microarray results, quantitative RT-PCR experiments
demonstrated higher expression of Notch2, Numb and
myogenin in mdx than in control mice at all ages (Figure
5).
Previous work by Conboy et al.[11] indicates the role of
the Notch-Delta signalling pathway in the regulation of
proliferation versus differentiation of asymmetrically
dividing satellite cells by Notch or Numb, respectively.
According to Delfini et al.[45], Notch is expressed in
immature myoblasts, while Delta (Dll) expressing cells
are more advanced in myogenesis (post-mitotic myob-
lasts and muscle fibres). Notch activation is thought to
inhibit transcription factors containing a basic helix loop
helix domain (bHLH) [46-50], via the induction of Hairy
and Enhancer of Split 1 (Hes1)[51], thereby inhibiting
myogenic differentiation. Numb-expressing cells are able
to undergo myogenic differentiation, because the Notch-
Delta pathway is inhibited (Figure 4A). Based on our
results, the Notch-Delta signalling pathway, notably the
expression of Notch or Numb, is responsible for the deter-
mination towards proliferation or differentiation of acti-
vated satellite cells in the mdx  mouse. Since gene
expression profiling detects proliferation and differentia-
tion processes simultaneously, satellite cell activation and
commitment are ongoing, parallel processes.
Bmp pathway
Various members of a Bmp-associated pathway (Bmp15,
Gdf9, Bmpr1a, Madh4, Inhbc, Inhbe, Inhba, and Idb2)
are differentially expressed in the mdx mouse (Figure 4B).
The gene expression of Bmp15, Bmpr1a, Inhbc, Inhbe,
and Idb2 is switched on in the mdx mouse, while expres-
sion cannot be detected in the control mouse. Bone Mor-
phogenetic Protein 15 (Bmp15) is a member of the
transforming growth factor-β (TGF-β) family. Bmp15
induces transcription of Inhibitors of DNA Binding pro-
teins (Idb1-3) via binding to Bone Morphogenetic Protein
Receptor type I (Bmpr1a), and the downstream transpor-
tation of Smad-complex (Madh8-Madh4) to the
nucleus[52,53]. Idb-proteins function as positive regula-
tors of cell growth by binding to Retinoblastoma 1 (Rb1).
This leads to the activation of the E2f transcription factor,
which plays a role in cell-cycle regulation. Furthermore,
Idb-proteins inhibit myogenic differentiation through
binding to MRFs[54]. The activation of Idb2 in the pre-
regeneration period is indicative of an inhibition of the
myogenic differentiation. This inhibition seems to be
Reconstruction of active regeneration pathways Figure 4
Reconstruction of active regeneration pathways. Regeneration-associated pathways were constructed based on differ-
entially expressed genes, literature study and gene ontology. Expression levels of genes in the Notch-Delta pathway (Panel A), 
the Bmp15 pathway (Panel B), and the Neuregulin3 pathway (Panel C) are plotted as fold-changes between mdx and control 
mice, as a function of age. In the pathway diagrams, filled boxes refer to upregulation (red) and downregulation (green) at 8 
weeks. Outlined boxes refer to upregulation (red) and downregulation (green) at other timepoints than 8 weeks. Shaded grey 
boxes represent genes which are not detected, or are not represented on the microarray. White boxes represent genes that 
show no differential expression between mdx and control mice.
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Confirmation of microarray data for genes in the Notch-Delta pathway by quantitative RT-PCR Figure 5
Confirmation of microarray data for genes in the Notch-Delta pathway by quantitative RT-PCR. Expression lev-
els of Notch2 (Panel A and B), Numb (Panel C and D), and Myogenin (Panel E and F) in mdx (grey circles) and wild-type (black 
squares) mice at 1 to 20 weeks of age were measured by quantitative RT-PCR (Panel A, C, E) and expression microarrays 
(Panel B, D, F). Expression levels relative to those in 1 week-old wild-type mice are plotted on a logarithmic scale (natural 
logarithm).
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alleviated during the regeneration period by a decrease in
differential expression of Idb2. Although most of the dif-
ferentially expressed genes in the Bmp pathway are con-
tinuously upregulated, the expression of a number of
genes peaks during regeneration (Inhbc, Inhbe, Bmp15,
and Gdf9)(Figure 4B). The Inhibin proteins (Inhbc/e),
likely to be antagonists of Bone Morphogenetic Pro-
teins[55], are also upregulated. Altogether, this points to a
positively and negatively controlled regulation of the
Bmp15 pathway. Our data suggests that the Bmp15 path-
way has an important function in the balancing of prolif-
eration and differentiation of myoblasts, necessary for
effective upscaling of muscle-mass.
Neuregulin pathway
In our study we found that several members of the Epider-
mal Growth Factor-like (EGF-like) Neuregulin pathway
are differentially expressed (Figure 4C). The signalling cas-
cade is activated by the binding of Neuregulin3 (Nrg3) to
the extracellular domain of the upregulated protein
tyrosine kinase v-erb-a erythroblastic leukemia viral onco-
gene homolog 4 (ErbB4)[56]. Both Nrg3 and ErbB4 are
expressed in the mdx mouse and cannot be detected in the
control mouse. The interaction between Nrg3 and ErbB4
activates epidermal growth factor-like signal transduction
via binding of the adaptor protein Growth factor receptor
bound protein 2 (Grb2), which peaks at the initiation of
regeneration (Figure 4C). Grb2 can activate Mitogen acti-
vated kinase kinase 1 (Map3k1)[57], whose differential
gene expression is increased at 2.5 weeks as well as during
regeneration. The activation of the MAP kinase pathways
eventually leads to transcriptional induction (reviewed
in[58]) through members of Activating protein complex 1
(Ap1), like Jund1 and Jun.
Depending on the protein complexes formed, specific
transcription activation will lead to different biological
processes ranging from proliferation to differentiation.
Furthermore, we find that other Grb-interacting proteins
like Vav 1 oncogene (Vav1)[59], and p21-activated kinase
1 (Pak1)[60] are switched on and upregulated, respec-
tively. The differential gene expression of Vav1 increases
during the initiation of regeneration, and might play a
role in the clustering of integrins for cell adhesion[61].
Pak1 differential gene expression is increased during
regeneration. Downstream genes activated by Pak1 regu-
late cytoskeletal dynamics, proliferation and cell survival
signalling[60]. Furthermore, our results show that the Erk
pathway is downregulated in the mdx mouse as well as the
p38 pathway.
Comparisons with other studies
In contrast to previously published studies of temporal
gene expression profiling in the mdx mouse [25-27], we
primarily focus on regeneration. The majority of differen-
tially expressed genes in regeneration (148 out of 166) in
our study have not been reported as differentially
expressed in the mdx mouse in other studies. Apart from
important differences in gene coverage (the Affymetrix
U74v2 GeneChips used in the other studies lack probe
sets for 22/166 genes), we explain the limited overlap by
differences in cut-off levels: as we applied very stringent
statistical tests, we could avoid setting a cut-off level for
the fold change, thereby picking up genes with small but
consistent fold changes, which can be biologically very
relevant, especially in the case of transcription factors.
This may also explain the large difference between the
study of Porter et al. and our study in the number of genes
found differentially expressed at the early timepoints (Fig-
ure 1), where mainly subtle expression changes are
expected.
Goetsch et al. reported results from a gene expression pro-
filing studies during muscle regeneration induced by car-
diotoxin injection in wildtype mice[62]. The authors
concluded that muscle regeneration is a complex process
that requires the coordinated modulation of the inflam-
matory response, myogenic precursor cells, growth fac-
tors, and the extracellular matrix for complete
regeneration of muscle architecture. A similar study of car-
diotoxin-induced muscle regeneration, recently published
by Zhao and Hoffman, reported that embryonic posi-
tional cues (Wnt, Shh, and Bmp) were not induced,
whereas expression of factors involved in satellite cell pro-
liferation and differentiation (MRFs, Pax, Notch1, and
FGFR4) was recapitulated[63]. Our study, which also
asserts satellite cell activation, proliferation, and differen-
tiation, shows differences in muscle regeneration between
mdx  and wildtype mice. Bmp and EGF-like signalling
pathways are activated during regeneration in the mdx
mouse, as well as upregulation of members of the Notch-
Delta pathway. In contrast to the upregulation of Pax7 in
wildtype mice, we have found upregulation of Pax3.
Altogether, these findings suggest that dystrophin-defi-
ciency might lead to enhanced regeneration processes in
hindlimb muscles over and above those found in
wildtype mice. It is likely that the regeneration pathways
identified in our study are also active in the mdx  dia-
phragm, given that the expression of their downstream
targets, the muscle regulatory factors myf-5, myoD, and
myogenin, are even more elevated in mdx diaphragm than
in hindlimb[64]. As demonstrated in another recent
study[65], the regeneration capacity per se is high and
does not explain why the muscle wasting in the mdx dia-
phragm is more severe than in the hindlimb. Other factors
such as higher workload and different involvement of the
immune system are likely to contribute.BMC Genomics 2005, 6:98 http://www.biomedcentral.com/1471-2164/6/98
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To discern active processes between the lethal human and
regenerative murine dystrophin-deficiency, the selected
murine gene expression profiles at 8 weeks of age were
compared to those of DMD patients[66]. Out of 166
regeneration-associated transcripts, 19 genes could be
detected that are differentially expressed in both the
human and murine muscular dystrophy (Additional file
5). Seven of these overlapping genes showed an opposite
differential expression between human DMD and mdx, of
which Platelet derived growth factor beta (Pdgfb) and
Paired box 3 (Pax3) are discussed below.
Gene expression of Pdgfb is upregulated in the mdx mouse
(18.6 fold), where it is downregulated (-1.7-fold) in DMD
patients. In the mdx mouse, Pdgfb shows an increase in
gene expression during regeneration (present in cluster 4,
Figure 3). Pdgfb was immunolocalized in infiltrating mac-
rophages, regenerating muscle fibres, and myofibre nuclei
of affected dystrophic muscle tissue[67]. The mitogen
Pdgfb stimulates myoblast proliferation, while inhibiting
myoblast differentiation[68]. It seems to have a similar
role during regeneration. Paired box 3 (Pax3) gene expres-
sion is activated in the mdx mouse relative to the control.
Its gene expression increases during regeneration, peaking
at 12 weeks of age, while hPax3 is downregulated in DMD
patients (-1.6-fold). Pax3 is capable of activating the
expression of the muscle regulatory factors Myod1, Myf5
or Myogenin, and thereby activating the myogenic
program[69].
The limited amount of overlapping genes between mdx
mice and human DMD patients, as well as a number of
genes showing opposite expression (i.e. Pdgfb and Pax3),
suggests that processes active in regenerating mouse mus-
cle are not active in human patients at the time gene
expression was profiled (Age: 5–12 years old). This corre-
sponds with clinical findings that patients older than 5
years have surpassed active regeneration processes[70].
The discovery of genes showing opposite regulation may
partly explain the differences in regeneration efficiency
and lethal manifestation of the pathology between dys-
trophin-deficient human and murine muscles.
Conclusion
Mdx mice lack a functional DGC at the sarcolemma. As a
consequence, gene expression of most DGC members is
downregulated.  Mdx  mice suffer from massive muscle
fibre necrosis starting at the age of 3 weeks. Regenerative
processes, starting approximately at the age of 6 weeks,
largely restore muscle tissue architecture, although muscle
fibres remain centrally nucleated. Recovered muscles of
mdx mice have slightly diminished strength and higher
fatigability. By analysing temporal expression profiles in
mdx and control mice, we have identified genes and path-
ways involved in regeneration. The expression of these
genes peaks between the ages of 6–12 weeks. Based on the
observation that several of these genes are not expressed
in control muscle and based on gene ontology classifica-
tion and further literature annotation, we suggest a role
for these genes in activation, proliferation, or differentia-
tion of satellite cells and myoblasts. We propose the fol-
lowing model (Figure 6). Muscular dystrophy leads to
muscle fibre necrosis, which attracts inflammatory cells,
and release of trophic factors. These factors activate quies-
cent satellite cells, which as a consequence start to prolif-
erate and differentiate. This divergent cell-fate is
controlled by the Notch-Delta pathway. Activated satellite
cells differentiate to myoblasts, which proliferate and dif-
ferentiate as well. The balance between these cell-fates
may be regulated by the level of Numb and the activation
of Bmp15 and Nrg3 signalling pathways. Differentiation
of myoblasts eventually leads to fusion with affected mus-
cle fibres or to the formation of new muscle fibres. The
genes and pathways active in regeneration are reminiscent
of embryonic myogenesis. We hypothesize that the newly
formed or repaired muscle fibres are similar to those in
the pre-necrotic phase, but are more able to adapt to dys-
trophin-deficiency through remodelling of muscle struc-
ture and fibre composition. Since many regeneration-
related genes remain higher expressed in mdx than in con-
trol muscle, it seems that regeneration processes are active
throughout the life span of the animal. Regenerative proc-
esses appear to be most effective when mice reach adult-
hood, and normal growth processes cease. Regeneration
and muscle development are both dependent on the
availability of satellite cells, and these processes will there-
fore compete for the satellite cell availability when acti-
vated simultaneously. In the human situation,
regeneration processes seem to be exhausted before
growth is finished. Together with the accumulation of
fibrotic and adipose tissue, exhaustion is thought to be the
reason of the lethal manifestation of the disease in human
patients. Prolongation of the regenerative capacity by acti-
vating the described pathways and/or replenishment with
a pool of 'regeneration-primed' cells may therefore pro-
vide an attractive strategy in the treatment of muscular
dystrophy.
Methods
Target preparation and hybridisation
Hindlimb muscle tissue was isolated from mdx (C57Bl/
10ScSnmdx/J (Jackson) × C57Bl/6NCrl (Charles River) ×
CBA/JCrl (Charles River)) and control (C57Bl/
10ScSnOlaHsd, Harland) at the ages of 1, 2 1/2, 4, 6, 8,
10, 12, 14, and 20 weeks (2 individuals per time point per
strain). Total RNA was isolated as described previously
(Turk  et al., submitted). cRNA was prepared by linear
amplification and concurrent incorporation of amino-
allyl UTP, followed by chemical coupling to monoreactive
Cy3 or Cy5 dyes[71]. Labelled targets (1.5 µg cRNA perBMC Genomics 2005, 6:98 http://www.biomedcentral.com/1471-2164/6/98
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target) were hybridised overnight on prehybridised
murine oligonucleotide microarrays (65-mer with 5'-hex-
ylaminolinker, Sigma-Genosys mouse 7.5K oligonucle-
otide library, printed in duplicate) using an automatic
hybridisation station (GeneTac, Genomic Solutions).
Posthybridisation washes were performed as described
previously[71].
Data analysis
Hybridisations were performed in a dye-swap fashion
using temporal loop-designs [72-74], enabling optimal
detection of gene expression differences between adjacent
time points for both mdx and control targets [see Addi-
tional file 2] Microarrays were analysed by GenePix Pro 3
feature extraction software (Axon). Local background-cor-
rected, median spot intensities were normalized simulta-
neously for all microarray experiments using Variance
Stabilization and Normalization (VSN) in R[75]. This
transformation coincides with the natural logarithm for
the high intensities. Array data has been made available
through the GEO data repository of the National Centre
for Biotechnology Information under series GSE1574.
Averaged (arithmetic mean) normalized intensities were
calculated per gene per time point for mdx and control
samples based upon 8 data points (2 biological replicates
with 4 technical replicates each). This method is more effi-
cient than ratio-based calculations for each hybridisa-
tion[76]. Genes were considered expressed when the
average normalized intensity was higher than the back-
ground level. The background level was determined by
calculating the averaged normalized intensity of 157
empty spots in all experiments plus 3 standard deviations.
Fold-changes in gene expression were calculated on a lin-
ear scale by subtraction of averaged normalized intensities
of control samples from mdx samples at each time point,
followed by returning e raised to the power of the differ-
ence. Maximum fold-changes per gene were determined
according to the highest fold-change within the time
course. Statistically significant differential gene expression
per gene per time point was calculated between mdx and
control samples by performing a two-tailed Student's t-
test assuming equal distributions. Significance levels were
set at 0.05 after applying a Bonferroni correction for mul-
tiple testing. Gene expression profiles were taken in con-
sideration when at least one time point showed
statistically significant differential gene expression
between mdx and control samples.
Comparisons with other gene expression studies were
facilitated by the program GeneHopper[77] that links
annotations for different platforms.
Schematic model of processes in regeneration Figure 6
Schematic model of processes in regeneration.
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Clustering
Temporal differential gene expression profiles were scaled
to time point t = 1 week. Selected profiles were grouped
using k-means clustering into a predetermined number of
clusters according to the correlation similarity measure
(Spotfire DecisionSite 7.1.1, Functional Genomics pack-
age). Clustering was initiated using evenly spaced profiles
as algorithm. This method generates profiles to be used as
centroids that are evenly distributed between the mini-
mum and maximum value for each variable in the
selected profiles (from Spotfire DecisionSite User's Guide
and Reference Manual).
Comparison with data from Duchenne patients
In a previous study, gene expression levels in 2 pools of
muscle RNA from 5 Duchenne patients (aged 5–6 years
and aged 10–12 years, respectively) and 2 pools of muscle
RNA from non-dystrophic controls (aged 5–12 years and
aged 4–13 years, respectively), were evaluated on Affyme-
trix U95A and U95Av2 GeneChips® [78]. We re-analysed
the gene expression data to obtain expression levels for all
genes, as well as the most recent annotation. To this end,
publicly available cel-files http://pepr.cnmcresearch.org
were loaded in Rosetta Resolver® Gene Expression Analy-
sis System v4.0 (Rosetta Biosoftware Inc., Seattle, WA).
Data were processed and normalized with the Rosetta
error model for Affymetrix U95A Genechips. Genes that
showed differential expression (p < 0.001 and absolute
fold-change >1.5) between the pools of dystrophic
patients and non-dystrophic controls were exported and
linked to mouse UniGene clusters with GeneHopper,
based on HomoloGene annotation.
Functional annotation
Gene Ontology annotation was developed by Compugen,
using nomenclature obtained from the Gene Ontology
consortium http://pepr.cnmcresearch.org. Additional
information was retrieved via OMIM and LocusLink http:/
/www.ncbi.nlm.nih.gov.
Quantitative RT-PCR
cDNA was synthesized by adding 40 ng of random hex-
amer primers to 1 µg of total RNA in a total volume of 11
µl. After denaturation for 10 min at 70°C and cooling for
10 min on ice, 4 µl of 5× first-strand buffer (MBI-Fermen-
tas), 2 µl of 10 mM dNTPs and 2 µl (200 U/µl) RevertAid
RNase H- (MBI-Fermentas) was added. The mixture was
incubated for 10 min at room temperature 2 hours at
42°C. The cDNA synthesis was halted by heating at
70°>C for 10 min. Quantitative PCR assays, using 10 µl of
20× diluted cDNA, were run on a MyIQ real-time PCR
detection system (BioRad), applying 36 cycles of 10 sec-
onds denaturation (95°C), 20 seconds annealing (60°C),
and 25 seconds extension (72°C). PCR mixtures con-
tained 1× PCR Buffer (Roche), 3 mM MgCl2, 225 µM of
each dNTP, 250 µg/ml BSA, 1× SYBR-Green (diluted from
10,000× stock, Molecular Probes), 10 nM fluorescein
(BioRad), 2.5 U homemade Taq polymerase, 0.25 U
AmpliTaq (Roche), and 10 pmol of forward and reverse
primers (for sequences see Additional file 3). The PCR effi-
ciencies, determined by analysis of a dilution series of a
mixture of all cDNA samples over 5 orders of magnitude,
ranged from 94.5% to 98% for the different primer pairs.
Melting curves were analyzed to confirm single product
formation. Gene expression levels were calculated using
the gene expression macro provided by BioRad and nor-
malized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, stable expression in all samples) expression
levels.
Abbreviations
DMD Duchenne muscular dystrophy
DGC Dystrophin-associated glycoprotein complex
NMJ Neuromuscular junction
VSN Variance stabilization and normalization
RT-PCR Reverse transcription followed by polymerase
chain reaction
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